Quick Answer
Zomedica Corp. reported R&D Expense of $7.17 million for fiscal year 2025.
Zomedica Corp. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.17M | -1.4% |
| 2024 | $7.27M | +26.5% |
| 2023 | $5.74M | +122.8% |
| 2022 | $2.58M | +54.1% |
| 2021 | $1.67M | -79.2% |
| 2020 | $8.04M | -22.2% |
| 2019 | $10.35M | +0.3% |
| 2018 | $10.32M | +275.0% |
| 2017 | $2.75M | +81.2% |
| 2016 | $1.52M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.78M | -3.3% | -5.4% |
| June 30, 2025 | $1.89M | +25.2% | +1.8% |
| March 31, 2025 | $1.85M | +4.6% | +0.4% |
| September 30, 2024 | $1.84M | +112.8% | +22.5% |
| June 30, 2024 | $1.51M | +75.3% | -15.0% |
| March 31, 2024 | $1.77M | +92.9% | +104.3% |
| September 30, 2023 | $867.0K | -28.6% | +0.9% |
| June 30, 2023 | $859.0K | +169.3% | -6.4% |
- Zomedica Corp. showed a decrease of -1.4% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Zomedica Corp.’s r&d expense has grown by 371.9% (from $1.52 million to $7.17 million).
- The most recent figure is from Zomedica Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: